Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameGan & Lee Pharmaceuticals Co Ltd
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









